◀ Back to IL8

IL8 — MAP2K1

Text-mined interactions from Literome

Rhee et al., J Biol Chem 2004 : Dominant negative MEK1 ( a kinase that activates ERK1/2 ) blocked flagellin stimulated IL-8 and MIP3alpha transcriptional activity, while the MEK-specific inhibitors PD98059 and U0126 reduced protein production of these cytokines ... Furthermore, overexpression of the constitutively active MEK1 induced IL-8 and MIP3alpha protein production
Lewthwaite et al., Int Immunopharmacol 2007 (Inflammation) : Selective inhibitors of p38 ( mapk ) ( SB203580 ) or of MEK1/2 , the direct upstream activator of ERK1/2 ( PD98059 ), reduced the synthesis of IL-1beta, TNFalpha, IL-6 and IL-8 induced by either the chaperonins or LPS
Hong et al., Vascul Pharmacol 2009 : The LPS induced activation of IL-8 promoter was attenuated by dominant negative MKK1 , but not by dominant negative MKK3
Watanabe et al., J Invest Dermatol 2009 (Psoriasis) : Next, we confirmed that selective mitogen activated protein kinase kinase inhibitors significantly inhibited IL-17F induced IL-8 production
Yang et al., Microvasc Res 2009 (AIDS Dementia Complex) : Inhibitors of STAT1, mitogen activated protein kinase kinase ( MEK ) ( PD98059 ), and phosphatidyl inositol 3 kinase (PI3K) ( LY294002 ), blocked gp120 induced STAT1 activation and significantly diminished IL-8- , IL-6-, and gp120 induced monocyte adhesion and migration across in vitro BBB models
Lau et al., Toxicological sciences : an official journal of the Society of Toxicology 2012 (MAP Kinase Signaling System) : Consistently, CSM induced IL-8 release was blocked by SB203580, U0126, or MEK1 small interfering RNA ( siRNA ) but not SP600125